- Home
- EVOK vs TOVX Comparison
EVOK vs TOVX Comparison
Compare EVOK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- TOVX
- Stock Information
- Founded
- EVOK 2007
- TOVX 2001
- Country
- EVOK United States
- TOVX United States
- Employees
- EVOK N/A
- TOVX N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- TOVX Health Care
- Exchange
- EVOK Nasdaq
- TOVX Nasdaq
- Market Cap
- EVOK 7.7M
- TOVX 4.5M
- IPO Year
- EVOK 2013
- TOVX 2006
- Fundamental
- Price
- EVOK $3.85
- TOVX $0.43
- Analyst Decision
- EVOK
- TOVX Hold
- Analyst Count
- EVOK 0
- TOVX 1
- Target Price
- EVOK N/A
- TOVX N/A
- AVG Volume (30 Days)
- EVOK 7.2M
- TOVX 184.6K
- Earning Date
- EVOK 08-12-2025
- TOVX 08-12-2025
- Dividend Yield
- EVOK N/A
- TOVX N/A
- EPS Growth
- EVOK N/A
- TOVX N/A
- EPS
- EVOK N/A
- TOVX N/A
- Revenue
- EVOK $11,594,083.00
- TOVX N/A
- Revenue This Year
- EVOK $57.82
- TOVX N/A
- Revenue Next Year
- EVOK $59.12
- TOVX N/A
- P/E Ratio
- EVOK N/A
- TOVX N/A
- Revenue Growth
- EVOK 89.89
- TOVX N/A
- 52 Week Low
- EVOK $1.94
- TOVX $0.40
- 52 Week High
- EVOK $12.32
- TOVX $7.23
- Technical
- Relative Strength Index (RSI)
- EVOK 46.17
- TOVX 36.49
- Support Level
- EVOK $4.26
- TOVX $0.45
- Resistance Level
- EVOK $4.70
- TOVX $0.52
- Average True Range (ATR)
- EVOK 0.43
- TOVX 0.03
- MACD
- EVOK -0.15
- TOVX 0.00
- Stochastic Oscillator
- EVOK 4.80
- TOVX 6.68
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.